Jufen Chu

4.3k total citations
5 papers, 55 citations indexed

About

Jufen Chu is a scholar working on Oncology, Pathology and Forensic Medicine and Statistics and Probability. According to data from OpenAlex, Jufen Chu has authored 5 papers receiving a total of 55 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Pathology and Forensic Medicine and 2 papers in Statistics and Probability. Recurrent topics in Jufen Chu's work include CAR-T cell therapy research (3 papers), Lymphoma Diagnosis and Treatment (2 papers) and Biomedical Ethics and Regulation (1 paper). Jufen Chu is often cited by papers focused on CAR-T cell therapy research (3 papers), Lymphoma Diagnosis and Treatment (2 papers) and Biomedical Ethics and Regulation (1 paper). Jufen Chu collaborates with scholars based in United States, Switzerland and Canada. Jufen Chu's co-authors include Sam Efromovich, Peter Borchmann, Ulrich Jaeger, Isabelle Fleury, Lida Pacaud, Edmund K. Waller, Alessandra Forcina, Peter A. Riedell, Nina Worel and Joseph P. McGuirk and has published in prestigious journals such as Blood, Blood Advances and Annals of the Institute of Statistical Mathematics.

In The Last Decade

Jufen Chu

5 papers receiving 51 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jufen Chu United States	4	43	27	13	9	9	5	55
Hatcher J. Ballard United States	7	65 1.5×	23 0.9×	10 0.8×	9 1.0×		11	70
Justin Chou United States	5	40 0.9×	12 0.4×	8 0.6×	17 1.9×		10	43
Erica Hong United States	3	38 0.9×	9 0.3×	7 0.5×	13 1.4×		5	53
Lisa Frölich Germany	2	27 0.6×	6 0.2×	10 0.8×	6 0.7×		6	31
Kimberly B. Sprenger United States	4	21 0.5×	8 0.3×	17 1.3×	12 1.3×		6	42
Séverine Mouraud France	2	21 0.5×	9 0.3×	15 1.2×	6 0.7×		4	36
Elizabeth Sirmans United States	3	38 0.9×	6 0.2×	10 0.8×	15 1.7×		4	49
Carolyn Muller United States	4	39 0.9×	8 0.3×	10 0.8×	16 1.8×		7	53
Barbara Pro United States	4	22 0.5×	17 0.6×	10 0.8×	5 0.6×		11	36
Neus Calbet‐Llopart Spain	6	31 0.7×	7 0.3×	16 1.2×	23 2.6×		11	55

Countries citing papers authored by Jufen Chu

Since Specialization

Citations

This map shows the geographic impact of Jufen Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jufen Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jufen Chu more than expected).

Fields of papers citing papers by Jufen Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jufen Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jufen Chu. The network helps show where Jufen Chu may publish in the future.

Co-authorship network of co-authors of Jufen Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Jufen Chu. A scholar is included among the top collaborators of Jufen Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jufen Chu. Jufen Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Hampson, Lisa V., Jufen Chu, Aiesha Zia, et al.. (2023). Combining the Target Trial and Estimand Frameworks to Define the Causal Estimand: An Application Using Real-World Data to Contextualize a Single-Arm Trial. Statistics in Biopharmaceutical Research. 16(1). 1–10. 5 indexed citations

2.

Salles, Gilles, Stephen J. Schuster, Martin Dreyling, et al.. (2022). Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Advances. 6(22). 5835–5843. 26 indexed citations

3.

Salles, Gilles, Stephen J. Schuster, Martin Dreyling, et al.. (2021). Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. Blood. 138(Supplement 1). 3528–3528. 3 indexed citations

4.

Jaeger, Ulrich, Nina Worel, Joseph P. McGuirk, et al.. (2019). Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood. 134(Supplement_1). 5325–5325. 17 indexed citations

5.

Efromovich, Sam & Jufen Chu. (2017). Hazard rate estimation for left truncated and right censored data. Annals of the Institute of Statistical Mathematics. 70(4). 889–917. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact